WallStSmart
TPST

Tempest Therapeutics Inc

NASDAQ: TPST · HEALTHCARE · BIOTECHNOLOGY

$1.92
-2.31% today

Updated 2026-06-05

Market cap
$18.80M
P/E ratio
P/S ratio
EPS (TTM)
$-5.70
Dividend yield
52W range
$1 – $12
Volume
0.2M

Tempest Therapeutics Inc (TPST) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201120122013201420152016201720182019202020212022202320242025
Revenue$9.73M$277000.00$653000.00$295000.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)-97.2%+135.7%-54.8%-100.0%
Cost of revenue$93000.00$231000.00$450000.00$2.25M$5.40M$28000.00$32000.00$1.05M$815000.00$1.27M$1.81M$381000.00$389000.00
Gross profit$9.73M$-1.97M$-4.75M$267000.00$-32000.00$-1.05M$-815000.00$-1.27M$-1.81M$-381000.00$-389000.00
Gross margin100.0%-711.9%-727.1%90.5%
R&D$1.17M$6.32M$15.80M$21.78M$18.43M$21.64M$14.53M$14.43M$27.84M$14.39M$17.17M$22.53M$17.50M$28.48M$12.61M
SG&A$7.21M$13.33M$26.15M$51.59M$49.22M$27.74M$8.69M$17.56M$4.91M$9.82M$12.11M$11.66M$13.55M$13.97M
Operating income$-2.62M$-13.53M$-29.13M$-47.93M$-72.00M$-81.01M$-20.48M$-23.12M$-45.40M$-19.30M$-26.99M$-34.64M$-29.16M$-42.03M$-26.57M
Operating margin-492.4%-25992.4%-12406.1%-6943.1%
EBITDA$-2.62M$-13.44M$-28.81M$-49.07M$-71.86M$-79.82M$-84.27M$-27.01M$-43.52M$-18.39M$-26.65M$-33.45M$-27.66M$-40.14M$-25.79M
EBITDA margin-504.1%-25941.5%-12223.7%-28566.1%
EBIT$-13.53M$-29.04M$-49.52M$-73.14M$-82.06M$-84.30M$-27.04M$-44.57M$-19.21M$-27.02M$-34.09M$-28.04M$-40.53M$-26.05M
Interest expense$0.00$0.00$0.00$436000.00$659000.00$0.00$134000.00$1.04M$507000.00$1.28M$1.62M$1.45M$1.32M$207000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-2.73M$-13.51M$-29.04M$-49.52M$-73.22M$-82.26M$-84.58M$-27.19M$-44.57M$-19.12M$-28.30M$-35.71M$-29.49M$-41.84M$-26.26M
Net income growth (YoY)-395.8%-115.0%-70.5%-47.9%-12.3%-2.8%+67.8%-63.9%+57.1%-48.0%-26.2%+17.4%-41.9%+37.2%
Profit margin-508.7%-26432.9%-12597.2%-28670.5%

Frequently asked questions

How much free cash flow does TPST generate?

TPST produced $-26.82M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TPST's balance sheet healthy?

TPST holds $7.71M in cash and equivalents against — in long-term debt, on $6.67M of shareholder equity. That debt is best read against the cash flow the business throws off each year.